{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:21:34Z","timestamp":1775546494025,"version":"3.50.1"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40121-023-00913-y","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T05:02:19Z","timestamp":1705640539000},"page":"21-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8560-3377","authenticated-orcid":false,"given":"Francisca","family":"Almeida-Pinto","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1667-7871","authenticated-orcid":false,"given":"Rui","family":"Pinto","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0303-8085","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Rocha","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"913_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41579-021-00639-z","volume":"20","author":"RE Baker","year":"2022","unstructured":"Baker RE, Mahmud AS, Miller IF, et al. Infectious disease in an era of global change. Nat Rev Microbiol. 2022;20:193\u2013205. https:\/\/doi.org\/10.1038\/s41579-021-00639-z.","journal-title":"Nat Rev Microbiol"},{"key":"913_CR2","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.pt.2018.07.004","volume":"34","author":"A Findlater","year":"2018","unstructured":"Findlater A, Bogoch II. Human mobility and the global spread of infectious diseases: a focus on air travel. Trends Parasitol. 2018;34:772\u201383. https:\/\/doi.org\/10.1016\/j.pt.2018.07.004.","journal-title":"Trends Parasitol"},{"key":"913_CR3","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.drudis.2021.06.019","volume":"26","author":"R Amaral","year":"2021","unstructured":"Amaral R, Torre C, Rocha J, Sepodes B. Ebola outbreaks: a stress test of the preparedness of medicines regulatory systems for public health crises. Drug Discov Today. 2021;26:2608\u201318. https:\/\/doi.org\/10.1016\/j.drudis.2021.06.019.","journal-title":"Drug Discov Today"},{"key":"913_CR4","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1038\/s41598-019-41192-3","volume":"9","author":"MUG Kraemer","year":"2019","unstructured":"Kraemer MUG, Golding N, Bisanzio D, et al. Utilizing general human movement models to predict the spread of emerging infectious diseases in resource poor settings. Sci Rep. 2019;9:5151. https:\/\/doi.org\/10.1038\/s41598-019-41192-3.","journal-title":"Sci Rep"},{"key":"913_CR5","unstructured":"The World Bank. Air transport, passengers carried. https:\/\/data.worldbank.org\/indicator\/IS.AIR.PSGR?end=2020&start=1970&type=shaded&view=chart. Accessed 4 Mar 2023."},{"key":"913_CR6","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.3390\/pathogens10101330","volume":"10","author":"S Jain","year":"2021","unstructured":"Jain S, Martynova E, Rizvanov A, Khaiboullina S, Baranwal M. Structural and functional aspects of Ebola virus proteins. Pathogens. 2021;10:1330. https:\/\/doi.org\/10.3390\/pathogens10101330.","journal-title":"Pathogens"},{"key":"913_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","volume":"6","author":"ST Jacob","year":"2020","unstructured":"Jacob ST, Crozier I, Fischer WA, et al. Ebola virus disease. Nat Rev Dis Prim. 2020;6:13. https:\/\/doi.org\/10.1038\/s41572-020-0147-3.","journal-title":"Nat Rev Dis Prim"},{"key":"913_CR8","unstructured":"World Health Organization. Therapeutics for Ebola virus disease. https:\/\/www.who.int\/publications\/i\/item\/9789240055742. Accessed 5 May 2023."},{"key":"913_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taz063","author":"AR Tuite","year":"2019","unstructured":"Tuite AR, Watts AG, Khan K, Bogoch II. Ebola virus outbreak in North Kivu and Ituri provinces, Democratic Republic of Congo, and the potential for further transmission through commercial air travel. J Travel Med. 2019. https:\/\/doi.org\/10.1093\/jtm\/taz063.","journal-title":"J Travel Med"},{"key":"913_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/B978-0-12-814515-9.00025-4","volume-title":"Encyclopedia of virology","author":"A Marzi","year":"2021","unstructured":"Marzi A, Banadyga L. Ebola virus (Filoviridae). In: Encyclopedia of virology. Amsterdam: Elsevier; 2021. p. 232\u201344."},{"key":"913_CR11","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","volume":"393","author":"D Malvy","year":"2019","unstructured":"Malvy D, McElroy AK, Clerck H, G\u00fcnther S, Griensven J. Ebola virus disease. Lancet. 2019;393:936\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(18)33132-5.","journal-title":"Lancet"},{"key":"913_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/v14030579","volume":"14","author":"CH Liu","year":"2022","unstructured":"Liu CH, Hu YT, Wong SH, Lin LT. Therapeutic strategies against Ebola virus infection. Viruses. 2022;14:579. https:\/\/doi.org\/10.3390\/v14030579.","journal-title":"Viruses"},{"key":"913_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/TME.0000000000000063","volume":"37","author":"KJ Richardson","year":"2015","unstructured":"Richardson KJ. Ebola virus disease. Adv Emerg Nurs J. 2015;37:102\u201315. https:\/\/doi.org\/10.1097\/TME.0000000000000063.","journal-title":"Adv Emerg Nurs J"},{"key":"913_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ajem.2023.04.037","volume":"70","author":"S Chavez","year":"2023","unstructured":"Chavez S, Koyfman A, Gottlieb M, et al. Ebola virus disease: a review for the emergency medicine clinician. Am J Emerg Med. 2023;70:30\u201340. https:\/\/doi.org\/10.1016\/j.ajem.2023.04.037.","journal-title":"Am J Emerg Med"},{"key":"913_CR15","unstructured":"ICTV. Current ICTV taxonomy release. https:\/\/ictv.global\/taxonomy. Accessed 25 Jun 2023."},{"key":"913_CR16","unstructured":"Kuhn JH, Biedenkopf N, Bukreyev A, et al. Rename two genera (Mononegavirales: Filoviridae). 2022. https:\/\/ictv.global\/files\/proposals\/approved?fid=11668#block-teamplus-page-title. Accessed 25 Jun 2023"},{"key":"913_CR17","unstructured":"Kuhn JH, Postler TS, Biedenkopf N, et al. Rename all species in the family to comply with the ICTV-mandated binomial format (Mononegavirales: Filoviridae). 2021. https:\/\/ictv.global\/files\/proposals\/approved?fid=11668#block-teamplus-page-title. Accessed 25 Jun 2023"},{"key":"913_CR18","unstructured":"ICTV. Approved proposals. https:\/\/ictv.global\/files\/proposals\/approved?fid=11668#block-teamplus-page-title. Accessed 25 Jun 2023."},{"key":"913_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1099\/jgv.0.001252","volume":"100","author":"JH Kuhn","year":"2019","unstructured":"Kuhn JH, Amarasinghe GK, Basler CF, et al. ICTV virus taxonomy profile: filoviridae. J Gen Virol. 2019;100:911\u20132. https:\/\/doi.org\/10.1099\/jgv.0.001252.","journal-title":"J Gen Virol"},{"key":"913_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.15585\/mmwr.su6503a2","volume":"65","author":"BP Bell","year":"2016","unstructured":"Bell BP, Damon IK, Jernigan DB, et al. Overview, control strategies, and lessons learned in the CDC response to the 2014\u20132016 Ebola epidemic. MMWR Suppl. 2016;65:4\u201311. https:\/\/doi.org\/10.15585\/mmwr.su6503a2.","journal-title":"MMWR Suppl"},{"key":"913_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41579-019-0187-4","volume":"17","author":"JH Kuhn","year":"2019","unstructured":"Kuhn JH, Adachi T, Adhikari NKJ, et al. New filovirus disease classification and nomenclature. Nat Rev Microbiol. 2019;17:261\u20133. https:\/\/doi.org\/10.1038\/s41579-019-0187-4.","journal-title":"Nat Rev Microbiol"},{"key":"913_CR22","unstructured":"Patel P, Shah S. Ebola virus\u2014StatPearls\u2014NCBI bookshelf. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560579\/#_NBK560579_pubdet_. Accessed 2 Apr 2023."},{"key":"913_CR23","volume-title":"Fields virology: emerging viruses","author":"PM Howley","year":"2020","unstructured":"Howley PM, Knipe DM, Whelan S. Fields virology: emerging viruses. 7th ed. USA: LWW; 2020.","edition":"7"},{"key":"913_CR24","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.1120453109","volume":"109","author":"TAM Bharat","year":"2012","unstructured":"Bharat TAM, Noda T, Riches JD, et al. Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography. Proc Natl Acad Sci USA. 2012;109:4275\u201380. https:\/\/doi.org\/10.1073\/pnas.1120453109.","journal-title":"Proc Natl Acad Sci USA"},{"key":"913_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029608","volume":"7","author":"DR Beniac","year":"2012","unstructured":"Beniac DR, Melito PL, Devarennes SL, et al. The organisation of Ebola virus reveals a capacity for extensive, modular polyploidy. PLoS One. 2012;7:e29608. https:\/\/doi.org\/10.1371\/journal.pone.0029608.","journal-title":"PLoS One"},{"key":"913_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-375156-0.00003-5","volume-title":"Fenner and White\u2019s medical virology","author":"CJ Burrell","year":"2017","unstructured":"Burrell CJ, Howard CR, Murphy FA. Virion structure and composition. In: Fenner and White\u2019s medical virology. Amsterdam: Elsevier; 2017. p. 27\u201337."},{"key":"913_CR27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/bfgp\/elx020","volume":"17","author":"P Dutta","year":"2018","unstructured":"Dutta P, Halder AK, Basu S, Kundu M. A survey on Ebola genome and current trends in computational research on the Ebola virus. Brief Funct Genomics. 2018;17:374\u201380. https:\/\/doi.org\/10.1093\/bfgp\/elx020.","journal-title":"Brief Funct Genomics"},{"key":"913_CR28","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.3389\/fmicb.2022.1026644","volume":"13","author":"W Furuyama","year":"2022","unstructured":"Furuyama W, Sakaguchi M, Yamada K, Nanbo A. Development of an imaging system for visualization of Ebola virus glycoprotein throughout the viral lifecycle. Front Microbiol. 2022;13:3910. https:\/\/doi.org\/10.3389\/fmicb.2022.1026644.","journal-title":"Front Microbiol"},{"key":"913_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010616","volume":"18","author":"O Dolnik","year":"2022","unstructured":"Dolnik O, Becker S. Assembly and transport of filovirus nucleocapsids. PLOS Pathog. 2022;18:e1010616. https:\/\/doi.org\/10.1371\/journal.ppat.1010616.","journal-title":"PLOS Pathog"},{"key":"913_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/9783527808656.ch3","volume-title":"Neglected tropical diseases: drug discovery and development","author":"MK Lo","year":"2019","unstructured":"Lo MK, Spengler JR, Erickson BR, Spiropoulou CF. Developing therapeutics for Ebola virus disease: a multifaceted approach. In: Neglected tropical diseases: drug discovery and development. New Jersey: Wiley; 2019. p. 49\u201391."},{"key":"913_CR31","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1016\/j.celrep.2019.08.047","volume":"28","author":"C Woolsey","year":"2019","unstructured":"Woolsey C, Menicucci AR, Cross RW, et al. A VP35 mutant Ebola virus lacks virulence but can elicit protective immunity to wild-type virus challenge. Cell Rep. 2019;28:3032. https:\/\/doi.org\/10.1016\/j.celrep.2019.08.047.","journal-title":"Cell Rep"},{"key":"913_CR32","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3390\/cells9051126","volume":"9","author":"J Brandt","year":"2020","unstructured":"Brandt J, Wendt L, Bodmer BS, Mettenleiter TC, Hoenen T. The cellular protein CAD is recruited into Ebola virus inclusion bodies by the nucleoprotein NP to facilitate genome replication and transcription. Cells. 2020;9:1126. https:\/\/doi.org\/10.3390\/cells9051126.","journal-title":"Cells"},{"key":"913_CR33","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s13238-020-00764-0","volume":"13","author":"L Wu","year":"2022","unstructured":"Wu L, Jin D, Wang D, et al. The two-stage interaction of Ebola virus VP40 with nucleoprotein results in a switch from viral RNA synthesis to virion assembly\/budding. Protein Cell. 2022;13:120\u201340. https:\/\/doi.org\/10.1007\/s13238-020-00764-0.","journal-title":"Protein Cell"},{"key":"913_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/boc.202200059","volume":"115","author":"C Diot","year":"2023","unstructured":"Diot C, Cosentino G, Rameix-Welti MA. Ribonucleoprotein transport in negative strand RNA viruses. Biol Cell. 2023;115:10. https:\/\/doi.org\/10.1111\/boc.202200059.","journal-title":"Biol Cell"},{"key":"913_CR35","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.molcel.2017.11.034","volume":"69","author":"T Kruse","year":"2018","unstructured":"Kruse T, Biedenkopf N, Hertz EPT, et al. The Ebola virus nucleoprotein recruits the host PP2A-B56 phosphatase to activate transcriptional support activity of VP30. Mol Cell. 2018;69:136\u2013145.e6. https:\/\/doi.org\/10.1016\/j.molcel.2017.11.034.","journal-title":"Mol Cell"},{"key":"913_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.antiviral.2018.06.003","volume":"156","author":"V Easton","year":"2018","unstructured":"Easton V, McPhillie M, Garcia-Dorival I, et al. Identification of a small molecule inhibitor of Ebola virus genome replication and transcription using in silico screening. Antiviral Res. 2018;156:46\u201354. https:\/\/doi.org\/10.1016\/j.antiviral.2018.06.003.","journal-title":"Antiviral Res"},{"key":"913_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/cells9010187","volume":"9","author":"L Wendt","year":"2020","unstructured":"Wendt L, Brandt J, Bodmer BS, et al. The Ebola virus nucleoprotein recruits the nuclear RNA export factor NXF1 into inclusion bodies to facilitate viral protein expression. Cells. 2020;9:187. https:\/\/doi.org\/10.3390\/cells9010187.","journal-title":"Cells"},{"key":"913_CR38","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1021\/acs.jproteome.6b00337","volume":"15","author":"I Garc\u00eda-Dorival","year":"2016","unstructured":"Garc\u00eda-Dorival I, Wu W, Armstrong SD, et al. Elucidation of the cellular interactome of Ebola virus nucleoprotein and identification of therapeutic targets. J Proteome Res. 2016;15:4290\u2013303. https:\/\/doi.org\/10.1021\/acs.jproteome.6b00337.","journal-title":"J Proteome Res"},{"key":"913_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00233-4","volume":"5","author":"Q Wan","year":"2020","unstructured":"Wan Q, Song D, Li H, Liang He M. Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development. Signal Transduct Target Ther. 2020;5:1\u201340. https:\/\/doi.org\/10.1038\/s41392-020-00233-4.","journal-title":"Signal Transduct Target Ther"},{"key":"913_CR40","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.virol.2015.02.017","volume":"479\u2013480","author":"AM Kell","year":"2015","unstructured":"Kell AM, Gale M. RIG-I in RNA virus recognition. Virology. 2015;479\u2013480:110\u201321. https:\/\/doi.org\/10.1016\/j.virol.2015.02.017.","journal-title":"Virology"},{"key":"913_CR41","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1089\/jir.2018.0163","volume":"39","author":"S Pattabhi","year":"2019","unstructured":"Pattabhi S, Knoll ML, Gale M, Loo YM. DHX15 is a coreceptor for RLR signaling that promotes antiviral defense against RNA virus infection. J Interf Cytokine Res. 2019;39:331. https:\/\/doi.org\/10.1089\/jir.2018.0163.","journal-title":"J Interf Cytokine Res"},{"key":"913_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105251","volume":"198","author":"A Corona","year":"2022","unstructured":"Corona A, Fanunza E, Salata C, et al. Cynarin blocks Ebola virus replication by counteracting VP35 inhibition of interferon-beta production. Antiviral Res. 2022;198: 105251. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105251.","journal-title":"Antiviral Res"},{"key":"913_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105554","volume":"212","author":"A Corona","year":"2023","unstructured":"Corona A, Strayer D, Distinto S, et al. Ebola virus disease: in vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod and its mechanism of action. Antiviral Res. 2023;212:105554. https:\/\/doi.org\/10.1016\/j.antiviral.2023.105554.","journal-title":"Antiviral Res"},{"key":"913_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030086","volume":"3","author":"J Haasnoot","year":"2007","unstructured":"Haasnoot J, De Vries W, Geutjes EJ, Prins M, De Haan P, Berkhout B. The Ebola virus VP35 protein is a suppressor of RNA silencing. PLOS Pathog. 2007;3:e86. https:\/\/doi.org\/10.1371\/journal.ppat.0030086.","journal-title":"PLOS Pathog"},{"key":"913_CR45","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1038\/s41467-022-29948-4","volume":"13","author":"L Zhu","year":"2022","unstructured":"Zhu L, Gao T, Huang Y, et al. Ebola virus VP35\u00a0hijacks the PKA-CREB1 pathway for replication and pathogenesis by AKIP1 association. Nat Commun. 2022;13:2256. https:\/\/doi.org\/10.1038\/s41467-022-29948-4.","journal-title":"Nat Commun"},{"key":"913_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00833-17","author":"P Bharaj","year":"2017","unstructured":"Bharaj P, Atkins C, Luthra P, et al. The host E3-ubiquitin ligase TRIM6 ubiquitinates the Ebola virus VP35 protein and promotes virus replication. J Virol. 2017. https:\/\/doi.org\/10.1128\/jvi.00833-17.","journal-title":"J Virol"},{"key":"913_CR47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.virol.2016.12.012","volume":"502","author":"V Le Sage","year":"2017","unstructured":"Le Sage V, Cinti A, McCarthy S, et al. Ebola virus VP35 blocks stress granule assembly. Virology. 2017;502:73\u201383. https:\/\/doi.org\/10.1016\/j.virol.2016.12.012.","journal-title":"Virology"},{"key":"913_CR48","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1172\/jci.insight.158902","volume":"7","author":"H Le","year":"2022","unstructured":"Le H, Spearman P, Waggoner SN, Singh K. Ebola virus protein VP40 stimulates IL-12- and IL-18-dependent activation of human natural killer cells. JCI Insight. 2022;7:16. https:\/\/doi.org\/10.1172\/jci.insight.158902.","journal-title":"JCI Insight"},{"key":"913_CR49","doi-asserted-by":"publisher","first-page":"55750","DOI":"10.18632\/oncotarget.18498","volume":"8","author":"DS Yu","year":"2017","unstructured":"Yu DS, Weng TH, Wu XX, et al. The lifecycle of the Ebola virus in host cells. Oncotarget. 2017;8:55750\u20139. https:\/\/doi.org\/10.18632\/oncotarget.18498.","journal-title":"Oncotarget"},{"key":"913_CR50","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202051709","volume":"23","author":"ML Husby","year":"2022","unstructured":"Husby ML, Amiar S, Prugar LI, et al. Phosphatidylserine clustering by the Ebola virus matrix protein is a critical step in viral budding. EMBO Rep. 2022;23:e51709. https:\/\/doi.org\/10.15252\/embr.202051709.","journal-title":"EMBO Rep"},{"key":"913_CR51","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1016\/j.bmcl.2016.06.053","volume":"26","author":"HM Loughran","year":"2016","unstructured":"Loughran HM, Han Z, Wrobel JE, et al. Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress. Bioorg Med Chem Lett. 2016;26:3429\u201335. https:\/\/doi.org\/10.1016\/j.bmcl.2016.06.053.","journal-title":"Bioorg Med Chem Lett"},{"key":"913_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009616","volume":"17","author":"L Zhang","year":"2021","unstructured":"Zhang L, Zhou S, Chen M, et al. P300-mediated NEDD4 acetylation drives ebolavirus VP40 egress by enhancing NEDD4 ligase activity. PLOS Pathog. 2021;17:e1009616. https:\/\/doi.org\/10.1371\/journal.ppat.1009616.","journal-title":"PLOS Pathog"},{"key":"913_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102375","volume":"106","author":"M Rojas","year":"2020","unstructured":"Rojas M, Monsalve DM, Pacheco Y, et al. Ebola virus disease: an emerging and re-emerging viral threat. J Autoimmun. 2020;106:102375. https:\/\/doi.org\/10.1016\/j.jaut.2019.102375.","journal-title":"J Autoimmun"},{"key":"913_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006349","volume":"12","author":"D Cantoni","year":"2018","unstructured":"Cantoni D, Rossman JS. Ebolaviruses: new roles for old proteins. PLoS Negl Trop Dis. 2018;12:e0006349. https:\/\/doi.org\/10.1371\/journal.pntd.0006349.","journal-title":"PLoS Negl Trop Dis"},{"key":"913_CR55","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/v11050410","volume":"11","author":"ML Pleet","year":"2019","unstructured":"Pleet ML, DeMarino C, Stonier SW, et al. Extracellular vesicles and Ebola virus: a new mechanism of immune evasion. Viruses. 2019;11:410. https:\/\/doi.org\/10.3390\/v11050410.","journal-title":"Viruses"},{"key":"913_CR56","doi-asserted-by":"publisher","first-page":"S365","DOI":"10.1093\/infdis\/jiy472","volume":"218","author":"ML Pleet","year":"2018","unstructured":"Pleet ML, Erickson J, Demarino C, et al. Ebola virus VP40 modulates cell cycle and biogenesis of extracellular vesicles. J Infect Dis. 2018;218:S365\u201387. https:\/\/doi.org\/10.1093\/infdis\/jiy472.","journal-title":"J Infect Dis"},{"key":"913_CR57","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.chom.2023.01.002","volume":"31","author":"V Rayaprolu","year":"2023","unstructured":"Rayaprolu V, Fulton BO, Rafique A, et al. Structure of the Inmazeb cocktail and resistance to Ebola virus escape. Cell Host Microbe. 2023;31:260\u2013272.e7. https:\/\/doi.org\/10.1016\/j.chom.2023.01.002.","journal-title":"Cell Host Microbe"},{"key":"913_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009937","volume":"17","author":"W Furuyama","year":"2021","unstructured":"Furuyama W, Shifflett K, Feldmann H, Marzi A. The Ebola virus soluble glycoprotein contributes to viral pathogenesis by activating the MAP kinase signaling pathway. PLOS Pathog. 2021;17:e1009937. https:\/\/doi.org\/10.1371\/journal.ppat.1009937.","journal-title":"PLOS Pathog"},{"key":"913_CR59","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/v11110999","volume":"11","author":"W Zhu","year":"2019","unstructured":"Zhu W, Banadyga L, Emeterio K, Wong G, Qiu X. The roles of Ebola virus soluble glycoprotein in replication, pathogenesis, and countermeasure development. Viruses. 2019;11:999. https:\/\/doi.org\/10.3390\/v11110999.","journal-title":"Viruses"},{"key":"913_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110172","volume":"38","author":"LI Melnik","year":"2022","unstructured":"Melnik LI, Guha S, Ghimire J, et al. Ebola virus delta peptide is an enterotoxin. Cell Rep. 2022;38:110172. https:\/\/doi.org\/10.1016\/j.celrep.2021.110172.","journal-title":"Cell Rep"},{"key":"913_CR61","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00438-17","author":"J He","year":"2017","unstructured":"He J, Melnik LI, Komin A, et al. Ebola virus delta peptide is a viroporin. J Virol. 2017. https:\/\/doi.org\/10.1128\/jvi.00438-17.","journal-title":"J Virol"},{"key":"913_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006848","volume":"14","author":"A Nanbo","year":"2018","unstructured":"Nanbo A, Maruyama J, Imai M, et al. Ebola virus requires a host scramblase for externalization of phosphatidylserine on the surface of viral particles. PLoS Pathog. 2018;14:e1006848. https:\/\/doi.org\/10.1371\/journal.ppat.1006848.","journal-title":"PLoS Pathog"},{"key":"913_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1083429","author":"E Taki","year":"2023","unstructured":"Taki E, Ghanavati R, Navidifar T, Dashtbin S, Heidary M, Moghadamnia M. Ebanga\u2122: the most recent FDA-approved drug for treating Ebola. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1083429.","journal-title":"Front Pharmacol"},{"key":"913_CR64","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.antiviral.2018.12.006","volume":"162","author":"CF Basler","year":"2019","unstructured":"Basler CF, Krogan NJ, Leung DW, Amarasinghe GK. Virus and host interactions critical for filoviral RNA synthesis as therapeutic targets. Antiviral Res. 2019;162:90. https:\/\/doi.org\/10.1016\/j.antiviral.2018.12.006.","journal-title":"Antiviral Res"},{"key":"913_CR65","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/s41401-023-01055-0","volume":"44","author":"Yh Ma","year":"2023","unstructured":"Ma Yh, Hong X, Wu F, et al. Inhibiting the transcription and replication of Ebola viruses by disrupting the nucleoprotein and VP30 protein interaction with small molecules. Acta Pharmacol Sin. 2023;44:1487\u201399. https:\/\/doi.org\/10.1038\/s41401-023-01055-0.","journal-title":"Acta Pharmacol Sin"},{"key":"913_CR66","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02565-19","author":"Y Takamatsu","year":"2020","unstructured":"Takamatsu Y, Kr\u00e4hling V, Kolesnikova L, et al. Serine\u2013arginine protein kinase 1 regulates ebola virus transcription. MBio. 2020. https:\/\/doi.org\/10.1128\/mbio.02565-19.","journal-title":"MBio"},{"key":"913_CR67","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01083-22","author":"Y Takamatsu","year":"2022","unstructured":"Takamatsu Y, Yoshikawa T, Kurosu T, et al. Role of VP30 phosphorylation in Ebola virus nucleocapsid assembly and transport. J Virol. 2022. https:\/\/doi.org\/10.1128\/jvi.01083-22.","journal-title":"J Virol"},{"key":"913_CR68","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3390\/v12080869","volume":"12","author":"Y Su","year":"2020","unstructured":"Su Y, Stahelin RV. The minor matrix protein VP24 from Ebola virus lacks direct lipid-binding properties. Viruses. 2020;12:869. https:\/\/doi.org\/10.3390\/v12080869.","journal-title":"Viruses"},{"key":"913_CR69","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/21505594.2021.1898169","volume":"12","author":"S Yamaoka","year":"2021","unstructured":"Yamaoka S, Ebihara H. Pathogenicity and virulence of ebolaviruses with species- and variant-specificity. Virulence. 2021;12:885\u2013901. https:\/\/doi.org\/10.1080\/21505594.2021.1898169.","journal-title":"Virulence"},{"key":"913_CR70","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/v15051075","volume":"15","author":"P Ramanathan","year":"2023","unstructured":"Ramanathan P, Tigabu B, Santos RI, et al. Ebolavirus species-specific interferon antagonism mediated by VP24. Viruses. 2023;15:1075. https:\/\/doi.org\/10.3390\/v15051075.","journal-title":"Viruses"},{"key":"913_CR71","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1128\/mbio.00972-21","volume":"12","author":"S Vidal","year":"2021","unstructured":"Vidal S, S\u00e1nchez-Aparicio M, Seoane R, et al. Expression of the Ebola virus VP24 protein compromises the integrity of the nuclear envelope and induces a laminopathy-like cellular phenotype. MBio. 2021;12:972\u201393. https:\/\/doi.org\/10.1128\/mbio.00972-21.","journal-title":"MBio"},{"key":"913_CR72","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1093\/nar\/gkw551","volume":"44","author":"A Ramanathan","year":"2016","unstructured":"Ramanathan A, Robb GB, Chan SH. mRNA capping: biological functions and applications. Nucleic Acids Res. 2016;44:7511\u201326. https:\/\/doi.org\/10.1093\/nar\/gkw551.","journal-title":"Nucleic Acids Res"},{"key":"913_CR73","doi-asserted-by":"publisher","first-page":"9051","DOI":"10.1093\/nar\/gkac722","volume":"50","author":"K Drazkowska","year":"2022","unstructured":"Drazkowska K, Tomecki R, Warminski M, et al. 2\u2032-O-Methylation of the second transcribed nucleotide within the mRNA 5\u2032 cap impacts the protein production level in a cell-specific manner and contributes to RNA immune evasion. Nucleic Acids Res. 2022;50:9051\u201371. https:\/\/doi.org\/10.1093\/nar\/gkac722.","journal-title":"Nucleic Acids Res"},{"key":"913_CR74","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.virol.2022.05.007","volume":"573","author":"FA Gourronc","year":"2022","unstructured":"Gourronc FA, Rebagliati MR, Kramer-Riesberg B, et al. Adipocytes are susceptible to Ebola virus infection. Virology. 2022;573:12\u201322. https:\/\/doi.org\/10.1016\/j.virol.2022.05.007.","journal-title":"Virology"},{"key":"913_CR75","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01165-21","author":"MD Acciani","year":"2021","unstructured":"Acciani MD, Lay Mendoza MF, Havranek KE, et al. Ebola virus requires phosphatidylserine scrambling activity for efficient budding and optimal infectivity. J Virol. 2021. https:\/\/doi.org\/10.1128\/jvi.01165-21.","journal-title":"J Virol"},{"key":"913_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000141","volume":"4","author":"MF Saeed","year":"2008","unstructured":"Saeed MF, Kolokoltsov AA, Freiberg AN, Holbrook MR, Davey RA. Phosphoinositide-3 Kinase-Akt pathway controls cellular entry of Ebola virus. PLOS Pathog. 2008;4:e1000141. https:\/\/doi.org\/10.1371\/journal.ppat.1000141.","journal-title":"PLOS Pathog"},{"key":"913_CR77","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41579-019-0233-2","volume":"17","author":"T Hoenen","year":"2019","unstructured":"Hoenen T, Groseth A, Feldmann H. Therapeutic strategies to target the Ebola virus life cycle. Nat Rev Microbiol. 2019;17:593\u2013606. https:\/\/doi.org\/10.1038\/s41579-019-0233-2.","journal-title":"Nat Rev Microbiol"},{"key":"913_CR78","doi-asserted-by":"publisher","first-page":"7473","DOI":"10.1128\/jvi.00136-12","volume":"86","author":"ME Miller","year":"2012","unstructured":"Miller ME, Adhikary S, Kolokoltsov AA, Davey RA. Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection. J Virol. 2012;86:7473\u201383. https:\/\/doi.org\/10.1128\/jvi.00136-12.","journal-title":"J Virol"},{"key":"913_CR79","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bsheal.2019.12.009","volume":"2","author":"C Jin","year":"2020","unstructured":"Jin C, Che B, Guo Z, et al. Single virus tracking of Ebola virus entry through lipid rafts in living host cells. Biosaf Heal. 2020;2:25\u201331. https:\/\/doi.org\/10.1016\/j.bsheal.2019.12.009.","journal-title":"Biosaf Heal"},{"key":"913_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100142","author":"A Carpinteiro","year":"2020","unstructured":"Carpinteiro A, Edwards MJ, Hoffmann M, et al. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Reports Med. 2020. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100142.","journal-title":"Cell Reports Med"},{"key":"913_CR81","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/v11030274","volume":"11","author":"C Salata","year":"2019","unstructured":"Salata C, Calistri A, Alvisi G, Celestino M, Parolin C, Pal\u00f9 G. Ebola virus entry: from molecular characterization to drug discovery. Viruses. 2019;11:274. https:\/\/doi.org\/10.3390\/v11030274.","journal-title":"Viruses"},{"key":"913_CR82","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01002-20","author":"Y Bo","year":"2020","unstructured":"Bo Y, Qiu S, Mulloy RP, C\u00f4t\u00e9 M. Filoviruses use the HOPS complex and UVRAG to traffic to Niemann-Pick C1 compartments during viral entry. J Virol. 2020. https:\/\/doi.org\/10.1128\/jvi.01002-20.","journal-title":"J Virol"},{"key":"913_CR83","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41467-018-08135-4","volume":"10","author":"M Flint","year":"2019","unstructured":"Flint M, Chatterjee P, Lin DL, et al. A genome-wide CRISPR screen identifies N-acetylglucosamine-1-phosphate transferase as a potential antiviral target for Ebola virus. Nat Commun. 2019;10:285. https:\/\/doi.org\/10.1038\/s41467-018-08135-4.","journal-title":"Nat Commun"},{"issue":"2","key":"913_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000626","volume":"18","author":"DK Das","year":"2020","unstructured":"Das DK, Bulow U, Diehl WE, et al. Conformational changes in the Ebola virus membrane fusion machine induced by pH, Ca2+, and receptor binding. PLoS Biol. 2020;18(2):e3000626. https:\/\/doi.org\/10.1371\/journal.pbio.3000626.","journal-title":"PLoS Biol"},{"key":"913_CR85","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00565-15","author":"AS Herbert","year":"2015","unstructured":"Herbert AS, Davidson C, Kuehne AI, et al. Niemann-pick C1 is essential for ebolavirus replication and pathogenesis in vivo. MBio. 2015. https:\/\/doi.org\/10.1128\/mbio.00565-15.","journal-title":"MBio"},{"key":"913_CR86","unstructured":"National Organization for Rare Disorders\u2014Niemann Pick disease type C\u2014symptoms, causes, treatment. https:\/\/rarediseases.org\/rare-diseases\/niemann-pick-disease-type-c\/. Accessed 8 Jun 2023."},{"key":"913_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0785-7","author":"T Geberhiwot","year":"2018","unstructured":"Geberhiwot T, Moro A, Dardis A, et al. Consensus clinical management guidelines for Niemann-Pick disease type C. Orphanet J Rare Dis. 2018. https:\/\/doi.org\/10.1186\/s13023-018-0785-7.","journal-title":"Orphanet J Rare Dis"},{"key":"913_CR88","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41594-020-00548-4","volume":"28","author":"J Lee","year":"2021","unstructured":"Lee J, Kreutzberger AJB, Odongo L, et al. Ebola virus glycoprotein interacts with cholesterol to enhance membrane fusion and cell entry. Nat Struct Mol Biol. 2021;28:181\u20139. https:\/\/doi.org\/10.1038\/s41594-020-00548-4.","journal-title":"Nat Struct Mol Biol"},{"key":"913_CR89","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3390\/v13050913","volume":"13","author":"M Igarashi","year":"2021","unstructured":"Igarashi M, Hirokawa T, Takadate Y, Takada A. Structural insights into the interaction of filovirus glycoproteins with the endosomal receptor Niemann-Pick C1: a computational study. Viruses. 2021;13:913. https:\/\/doi.org\/10.3390\/v13050913.","journal-title":"Viruses"},{"key":"913_CR90","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1126\/science.1258758","volume":"347","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Kolokoltsov AA, Chen CC, et al. Two pore channels control Ebolavirus host cell entry and are drug targets for disease treatment. Science. 2015;347:995\u20138. https:\/\/doi.org\/10.1126\/science.1258758.","journal-title":"Science"},{"key":"913_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2022.102528","volume":"102","author":"GS Gunaratne","year":"2022","unstructured":"Gunaratne GS, Marchant JS. The ins and outs of virus trafficking through acidic Ca2+ stores. Cell Calcium. 2022;102:102528. https:\/\/doi.org\/10.1016\/j.ceca.2022.102528.","journal-title":"Cell Calcium"},{"key":"913_CR92","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.bbamcr.2018.10.022","volume":"1866","author":"CJ Penny","year":"2019","unstructured":"Penny CJ, Vassileva K, Jha A, et al. Mining of Ebola virus entry inhibitors identifies approved drugs as two-pore channel pore blockers. Biochim Biophys Acta Mol Cell Res. 2019;1866:1151\u201361. https:\/\/doi.org\/10.1016\/j.bbamcr.2018.10.022.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"913_CR93","doi-asserted-by":"publisher","first-page":"6481","DOI":"10.1128\/jvi.03156-14\/","volume":"89","author":"M Kuroda","year":"2015","unstructured":"Kuroda M, Fujikura D, Nanbo A, et al. Interaction between TIM-1 and NPC1 is important for cellular entry of Ebola virus. J Virol. 2015;89:6481\u201393. https:\/\/doi.org\/10.1128\/jvi.03156-14\/.","journal-title":"J Virol"},{"key":"913_CR94","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.virol.2017.09.028","volume":"513","author":"S Qiu","year":"2018","unstructured":"Qiu S, Leung A, Bo Y, et al. Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry. Virology. 2018;513:17\u201328. https:\/\/doi.org\/10.1016\/j.virol.2017.09.028.","journal-title":"Virology"},{"key":"913_CR95","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2023113578","author":"SL Winter","year":"2023","unstructured":"Winter SL, Golani G, Lolicato F, et al. The Ebola virus VP40 matrix layer undergoes endosomal disassembly essential for membrane fusion. EMBO J. 2023. https:\/\/doi.org\/10.15252\/embj.2023113578.","journal-title":"EMBO J"},{"key":"913_CR96","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2016.11.011","volume":"137","author":"N Biedenkopf","year":"2017","unstructured":"Biedenkopf N, Lange-Gr\u00fcnweller K, Schulte FW, et al. The natural compound silvestrol is a potent inhibitor of Ebola virus replication. Antiviral Res. 2017;137:76\u201381. https:\/\/doi.org\/10.1016\/j.antiviral.2016.11.011.","journal-title":"Antiviral Res"},{"key":"913_CR97","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11262-019-01641-7","volume":"55","author":"H Montero","year":"2019","unstructured":"Montero H, P\u00e9rez-Gil G, Sampieri CL. Eukaryotic initiation factor\u00a04A (eIF4A) during viral infections. Virus Genes. 2019;55:267\u201373. https:\/\/doi.org\/10.1007\/s11262-019-01641-7.","journal-title":"Virus Genes"},{"key":"913_CR98","doi-asserted-by":"publisher","first-page":"2223727","DOI":"10.1080\/22221751.2023.2223727","volume":"12","author":"BS Bodmer","year":"2023","unstructured":"Bodmer BS, Vallbracht M, Ushakov DS, Wendt L, Chlanda P, Hoenen T. Ebola virus inclusion bodies are liquid organelles whose formation is facilitated by nucleoprotein oligomerization. Emerg Microbes Infect. 2023;12:2223727. https:\/\/doi.org\/10.1080\/22221751.2023.2223727.","journal-title":"Emerg Microbes Infect"},{"key":"913_CR99","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nrm2406","volume":"9","author":"PK Mattila","year":"2008","unstructured":"Mattila PK, Lappalainen P. Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol. 2008;9:446\u201354. https:\/\/doi.org\/10.1038\/nrm2406.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"913_CR100","doi-asserted-by":"publisher","first-page":"e683","DOI":"10.1016\/S2666-5247(22)00123-9","volume":"3","author":"Y Gao","year":"2022","unstructured":"Gao Y, Zhao Y, Guyatt G, et al. Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis. Lancet Microbe. 2022;3:e683\u2013692. https:\/\/doi.org\/10.1016\/S2666-5247(22)00123-9.","journal-title":"Lancet Microbe"},{"key":"913_CR101","unstructured":"UpToDate. Society guideline links: infection control\u2014up to date. https:\/\/www.uptodate.com\/contents\/society-guideline-links-infection-control?search=ebola&topicRef=113258&source=see_link. Accessed 30 Apr 2023."},{"key":"913_CR102","unstructured":"World Health Organization. Optimized supportive care for Ebola virus disease: clinical management standard operating procedures. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/325000\/9789241515894-eng.pdf. Accessed 8 May\u00a02023."},{"key":"913_CR103","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu S, Dodd LE, Davey RT, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381:2293\u2013303. https:\/\/doi.org\/10.1056\/NEJMoa1910993.","journal-title":"N Engl J Med"},{"key":"913_CR104","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","volume":"375","author":"The PREVAIL II Writing Group for the Multi-National PREVAIL II Study Team","year":"2016","unstructured":"The PREVAIL II Writing Group for the Multi-National PREVAIL II Study Team. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med. 2016;375:1448\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1604330.","journal-title":"N Engl J Med"},{"key":"913_CR105","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.1128\/jvi.00406-16","volume":"90","author":"EEH Tran","year":"2016","unstructured":"Tran EEH, Nelson EA, Bonagiri P, et al. Mapping of Ebolavirus neutralization by monoclonal antibodies in the ZMapp cocktail using cryo-electron tomography and studies of cellular entry. J Virol. 2016;90:7618\u201327. https:\/\/doi.org\/10.1128\/jvi.00406-16.","journal-title":"J Virol"},{"key":"913_CR106","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/bs.podrm.2022.11.003","volume":"48","author":"AH Bakheit","year":"2023","unstructured":"Bakheit AH, Darwish H, Darwish IA, Al-Ghusn AI. Remdesivir. Profiles Drug Subst Excip Relat Methodol. 2023;48:71\u2013108. https:\/\/doi.org\/10.1016\/bs.podrm.2022.11.003.","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"913_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.721328","author":"O TshianiMbaya","year":"2021","unstructured":"TshianiMbaya O, Mukumbayi P, Mulangu S. Review: insights on current FDA-approved monoclonal antibodies against Ebola virus infection. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.721328.","journal-title":"Front Immunol"},{"key":"913_CR108","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3390\/vaccines10081213","volume":"10","author":"I Crozier","year":"2022","unstructured":"Crozier I, Britson KA, Wolfe DN, et al. The evolution of medical countermeasures for Ebola virus disease: lessons learned and next steps. Vaccines. 2022;10:1213. https:\/\/doi.org\/10.3390\/vaccines10081213.","journal-title":"Vaccines"},{"key":"913_CR109","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1056\/NEJMc2113505","volume":"386","author":"S Mulangu","year":"2022","unstructured":"Mulangu S, Mbala-Kingebeni P, Mbaya OT. Antibody use during an outbreak of Ebola virus disease in the democratic Republic of Congo, 2020. N Engl J Med. 2022;386:1188\u201391. https:\/\/doi.org\/10.1056\/NEJMc2113505.","journal-title":"N Engl J Med"},{"key":"913_CR110","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40265-020-01452-3","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. REGN-EB3: first approval. Drugs. 2021;81:175\u20138. https:\/\/doi.org\/10.1007\/s40265-020-01452-3.","journal-title":"Drugs"},{"key":"913_CR111","unstructured":"FDA. Inmazeb\u00ae leaflet. www.fda.gov\/medwatch. Accessed 23 May\u00a02023."},{"key":"913_CR112","unstructured":"Inmazeb: The first FDA-approved treatment for Zaire ebolavirus. https:\/\/www.inmazeb.com\/. Accessed 23 May\u00a02023."},{"key":"913_CR113","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41579-020-0354-7","volume":"18","author":"N Di Paola","year":"2020","unstructured":"Di Paola N, Sanchez-Lockhart M, Zeng X, Kuhn JH, Palacios G. Viral genomics in Ebola virus research. Nat Rev Microbiol. 2020;18:365\u201378. https:\/\/doi.org\/10.1038\/s41579-020-0354-7.","journal-title":"Nat Rev Microbiol"},{"key":"913_CR114","unstructured":"European Medicines Agency. Ebola. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/ebola#ebola-outbreak-in-2018-19-section. Accessed 23 May\u00a02023."},{"key":"913_CR115","unstructured":"EMA. Public summary of opinion on orphan designation Three human monoclonal antibodies against the EBOV glycoprotein for the treatment of Ebola virus disease. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-18-2027. Accessed 26 May\u00a02023."},{"key":"913_CR116","unstructured":"EMA. EU\/3\/18\/2027: Orphan designation for the treatment of Ebola virus disease. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-18-2027. Accessed 28 May\u00a02023."},{"key":"913_CR117","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s40265-021-01483-4","volume":"81","author":"Arnold Lee","year":"2021","unstructured":"Ansuvimab LA. First approval. Drugs. 2021;81:595\u20138. https:\/\/doi.org\/10.1007\/s40265-021-01483-4.","journal-title":"Drugs"},{"key":"913_CR118","unstructured":"Ebanga\u2122. https:\/\/www.ebanga.com\/. Accessed 21 May\u00a02023."},{"key":"913_CR119","unstructured":"FDA. Ebanga\u2122 leaflet. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761172s000lbl.pdf. Accessed 21 May 2023"},{"key":"913_CR120","unstructured":"Black L, Wittman M, Wagner J. Treating Zaire ebolavirus with Ansuvimab-zykl. Contag Infect Dis Today. 2021;6. https:\/\/www.contagionlive.com\/view\/treating-zaire-ebolavirus-with-ansuvimab-zykl."},{"key":"913_CR121","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/22221751.2021.2020598","volume":"11","author":"S Kummer","year":"2022","unstructured":"Kummer S, Lander A, Goretzko J, Kirchoff N, Rescher U, Schloer S. Pharmacologically induced endolysosomal cholesterol imbalance through clinically licensed drugs itraconazole and fluoxetine impairs Ebola virus infection in vitro. Emerg Microbes Infect. 2022;11:195\u2013207. https:\/\/doi.org\/10.1080\/22221751.2021.2020598.","journal-title":"Emerg Microbes Infect"},{"key":"913_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105294","volume":"200","author":"B Vanmechelen","year":"2022","unstructured":"Vanmechelen B, Stroobants J, Chiu W, et al. Identification of novel Ebola virus inhibitors using biologically contained virus. Antiviral Res. 2022;200:105294. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105294.","journal-title":"Antiviral Res"},{"key":"913_CR123","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00168-19","author":"N Kumar","year":"2020","unstructured":"Kumar N, Sharma S, Kumar R, et al. Host-directed antiviral therapy. Clin Microbiol Rev. 2020. https:\/\/doi.org\/10.1128\/cmr.00168-19.","journal-title":"Clin Microbiol Rev"},{"key":"913_CR124","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12967-020-02476-9","volume":"18","author":"VC Chitalia","year":"2020","unstructured":"Chitalia VC, Munawar AH. A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals. J Transl Med. 2020;18:390. https:\/\/doi.org\/10.1186\/s12967-020-02476-9.","journal-title":"J Transl Med"},{"key":"913_CR125","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01031-17","author":"KM Peck","year":"2018","unstructured":"Peck KM, Lauring AS. Complexities of viral mutation rates. J Virol. 2018. https:\/\/doi.org\/10.1128\/jvi.01031-17.","journal-title":"J Virol"},{"key":"913_CR126","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.antiviral.2017.12.008","volume":"150","author":"J Ma","year":"2018","unstructured":"Ma J, Zhang X, Soloveva V, et al. Enhancing the antiviral potency of ER \u03b1-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo. Antiviral Res. 2018;150:112\u201322. https:\/\/doi.org\/10.1016\/j.antiviral.2017.12.008.","journal-title":"Antiviral Res"},{"key":"913_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2021.116356","volume":"46","author":"S Mahajan","year":"2021","unstructured":"Mahajan S, Choudhary S, Kumar P, Tomar S. Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens. Bioorg Med Chem. 2021;46:116356. https:\/\/doi.org\/10.1016\/j.bmc.2021.116356.","journal-title":"Bioorg Med Chem"},{"key":"913_CR128","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3390\/v15030776","volume":"15","author":"VC Roa-Linares","year":"2023","unstructured":"Roa-Linares VC, Escudero-Fl\u00f3rez M, Vicente-Manzanares M, Gallego-G\u00f3mez JC. Host cell targets for unconventional antivirals against RNA viruses. Viruses. 2023;15:776. https:\/\/doi.org\/10.3390\/v15030776.","journal-title":"Viruses"},{"key":"913_CR129","doi-asserted-by":"publisher","DOI":"10.3389\/fviro.2022.935933","author":"R Badia","year":"2022","unstructured":"Badia R, Garcia-Vidal E, Ballana E. Viral-host dependency factors as therapeutic targets to overcome antiviral drug-resistance: a focus on innate immune modulation. Front Virol. 2022. https:\/\/doi.org\/10.3389\/fviro.2022.935933.","journal-title":"Front Virol"},{"key":"913_CR130","doi-asserted-by":"publisher","first-page":"S425","DOI":"10.1093\/infdis\/jiv223","volume":"212","author":"A Basu","year":"2015","unstructured":"Basu A, Mills DM, Mitchell D, et al. Novel small molecule entry inhibitors of Ebola virus. J Infect Dis. 2015;212:S425\u201334. https:\/\/doi.org\/10.1093\/infdis\/jiv223.","journal-title":"J Infect Dis"},{"key":"913_CR131","doi-asserted-by":"publisher","first-page":"113654","DOI":"10.1016\/j.ejmech.2021.113654","volume":"223","author":"M Morales-Tenorio","year":"2021","unstructured":"Morales-Tenorio M, Ginex T, Cuesta-Geijo MA, et al. Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction. Eur J Med Chem. 2021;223:113654. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113654.","journal-title":"Eur J Med Chem"},{"key":"913_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-016-0941-9","author":"Z Zhao","year":"2016","unstructured":"Zhao Z, Martin C, Fan R, Bourne PE, Xie L. Drug repurposing to target Ebola virus replication and virulence using structural systems pharmacology. BMC Bioinform. 2016. https:\/\/doi.org\/10.1186\/s12859-016-0941-9.","journal-title":"BMC Bioinform"},{"key":"913_CR133","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s11094-022-02778-w","volume":"56","author":"N Rao","year":"2022","unstructured":"Rao N, Poojari T, Poojary C, Sande R, Sawant S. Drug repurposing: a shortcut to new biological entities. Pharm Chem J. 2022;56:1203\u201314. https:\/\/doi.org\/10.1007\/s11094-022-02778-w.","journal-title":"Pharm Chem J"},{"key":"913_CR134","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01803","author":"K Dhama","year":"2018","unstructured":"Dhama K, Karthik K, Khandia R, et al. Advances in designing and developing vaccines, drugs, and therapies to counter Ebola virus. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.01803.","journal-title":"Front Immunol"},{"key":"913_CR135","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.antiviral.2016.11.017","volume":"137","author":"W Sun","year":"2017","unstructured":"Sun W, He S, Mart\u00ednez-Romero, et al. Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Res. 2017;137:165\u201372. https:\/\/doi.org\/10.1016\/j.antiviral.2016.11.017.","journal-title":"Antiviral Res"},{"key":"913_CR136","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00660-18","author":"P Shrivastava-Ranjan","year":"2018","unstructured":"Shrivastava-Ranjan P, Flint M, Bergeron \u00c9, et al. Statins suppress Ebola virus infectivity by interfering with glycoprotein processing. MBio. 2018. https:\/\/doi.org\/10.1128\/mbio.00660-18.","journal-title":"MBio"},{"key":"913_CR137","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.3390\/jcm11195626","volume":"11","author":"BR Wu","year":"2022","unstructured":"Wu BR, Chen DH, Liao WC, et al. Statin therapy and the risk of viral infection: a retrospective population-based cohort study. J Clin Med. 2022;11:5626. https:\/\/doi.org\/10.3390\/jcm11195626.","journal-title":"J Clin Med"},{"key":"913_CR138","doi-asserted-by":"publisher","DOI":"10.1002\/med.21664","author":"X Ji","year":"2020","unstructured":"Ji X, Li Z. Medicinal chemistry strategies toward host targeting antiviral agents. Med Res Rev. 2020. https:\/\/doi.org\/10.1002\/med.21664.","journal-title":"Med Res Rev"},{"key":"913_CR139","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1016\/j.apsb.2022.05.023","volume":"12","author":"D Yi","year":"2022","unstructured":"Yi D, Li Q, Wang H, et al. Repurposing of berbamine hydrochloride to inhibit Ebola virus by targeting viral glycoprotein. Acta Pharm Sin B. 2022;12:4378\u201389. https:\/\/doi.org\/10.1016\/j.apsb.2022.05.023.","journal-title":"Acta Pharm Sin B"},{"key":"913_CR140","unstructured":"FDA. Drug Approvals and Databases. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-approvals-and-databases. Accessed 13 Jun 2023."},{"key":"913_CR141","unstructured":"European Medicines Agency. Medicines. https:\/\/www.ema.europa.eu\/en\/medicines. Accessed 13 Jun 2023."},{"key":"913_CR142","unstructured":"DrugBank Online. Database for drug and drug target info. https:\/\/go.drugbank.com\/. Accessed 25 Jun 2023."},{"key":"913_CR143","doi-asserted-by":"publisher","first-page":"24838","DOI":"10.1021\/acsomega.0c03527","volume":"5","author":"W Zhao","year":"2020","unstructured":"Zhao W, Bai B, Hong Z, Zhang X, Zhou B. Berbamine (BBM), a natural STAT3 inhibitor, synergistically enhances the antigrowth and proapoptotic effects of sorafenib on hepatocellular carcinoma cells. ACS Omega. 2020;5:24838\u201347. https:\/\/doi.org\/10.1021\/acsomega.0c03527.","journal-title":"ACS Omega"},{"key":"913_CR144","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.3390\/ijms24076298","volume":"24","author":"E Broni","year":"2023","unstructured":"Broni E, Ashley C, Adams J, et al. Cheminformatics-based study identifies potential Ebola VP40 inhibitors. Int J Mol Sci. 2023;24:6298. https:\/\/doi.org\/10.3390\/ijms24076298.","journal-title":"Int J Mol Sci"},{"key":"913_CR145","unstructured":"European Medicines Agency. EU\/3\/15\/1480. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu3151480. Accessed 18 Jun 2023."},{"key":"913_CR146","doi-asserted-by":"publisher","first-page":"217","DOI":"10.24123\/mpi.v3i4.4716","volume":"3","author":"Y Antonius","year":"2021","unstructured":"Antonius Y, Ongko J, Sukweenadhi J, Putra SED. Identification of potential Ebola virus nucleoprotein (EBOV NP) inhibitor derivate from various traditional medicinal plants in Indonesia: in silico study. Media Pharm Indonesia. 2021;3:217\u201326. https:\/\/doi.org\/10.24123\/mpi.v3i4.4716.","journal-title":"Media Pharm Indonesia"},{"key":"913_CR147","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41586-022-05271-2","volume":"610","author":"B Yuan","year":"2022","unstructured":"Yuan B, Peng Q, Cheng J, et al. Structure of the Ebola virus polymerase complex. Nature. 2022;610:394\u2013401. https:\/\/doi.org\/10.1038\/s41586-022-05271-2.","journal-title":"Nature"},{"key":"913_CR148","unstructured":"African sleeping sickness. https:\/\/www.bayer.com\/en\/pharma\/african-sleeping-sickness. Accessed 18 Jun 2023."},{"key":"913_CR149","unstructured":"WHO\u2014Electronic essential medicines list. https:\/\/list.essentialmeds.org\/recommendations\/819. Accessed 18 Jun 2023."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00913-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-023-00913-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00913-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T13:18:20Z","timestamp":1706620700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-023-00913-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":149,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["913"],"URL":"https:\/\/doi.org\/10.1007\/s40121-023-00913-y","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"22 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Francisca Almeida-Pinto, Jo\u00e3o Rocha, and Rui Pinto declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}